NASDAQ:ZIOP - ZIOPHARM Oncology Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ZIOPHARM Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.42 -0.07 (-1.56 %) (As of 01/26/2020 01:58 PM ET) Add Compare Today's Range$4.28Now: $4.42▼$4.5450-Day Range$4.42MA: $4.83▼$5.2452-Week Range$1.95Now: $4.42▼$7.25Volume2.02 million shsAverage Volume1.80 million shsMarket Capitalization$800.15 millionP/E Ratio6.41Dividend YieldN/ABeta2.58 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ZIOP Previous Symbol CUSIP98973P10 CIK1107421 Webhttp://www.ziopharm.com/ Phone617-259-1970Debt Debt-to-Equity Ratio0.01 Current Ratio10.34 Quick Ratio10.34Price-To-Earnings Trailing P/E Ratio6.41 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$150,000.00 Price / Sales5,334.35 Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book7.37Profitability EPS (Most Recent Fiscal Year)($0.48) Net Income$-53,120,000.00 Net MarginsN/A Return on Equity-318.78% Return on Assets-282.76%Miscellaneous Employees48 Outstanding Shares181,030,000Market Cap$800.15 million Next Earnings Date3/3/2020 (Estimated) OptionableOptionable Receive ZIOP News and Ratings via Email Sign-up to receive the latest news and ratings for ZIOP and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ZIOP Rates by TradingView ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions What is ZIOPHARM Oncology's stock symbol? ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP." How were ZIOPHARM Oncology's earnings last quarter? ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) released its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.43) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.34. View ZIOPHARM Oncology's Earnings History. When is ZIOPHARM Oncology's next earnings date? ZIOPHARM Oncology is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for ZIOPHARM Oncology. What price target have analysts set for ZIOP? 4 brokerages have issued 12-month price objectives for ZIOPHARM Oncology's shares. Their forecasts range from $6.50 to $7.50. On average, they expect ZIOPHARM Oncology's stock price to reach $6.88 in the next year. This suggests a possible upside of 55.5% from the stock's current price. View Analyst Price Targets for ZIOPHARM Oncology. What is the consensus analysts' recommendation for ZIOPHARM Oncology? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ZIOPHARM Oncology. Has ZIOPHARM Oncology been receiving favorable news coverage? Media stories about ZIOP stock have been trending extremely negative on Sunday, InfoTrie reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ZIOPHARM Oncology earned a news sentiment score of -4.5 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for ZIOPHARM Oncology. Who are some of ZIOPHARM Oncology's key competitors? Some companies that are related to ZIOPHARM Oncology include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of ZIOPHARM Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Intrexon (XON), Celgene (CELG), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Arena Pharmaceuticals (ARNA), Immunomedics (IMMU), Opko Health (OPK), Amarin (AMRN), Sarepta Therapeutics (SRPT) and Inovio Pharmaceuticals (INO). Who are ZIOPHARM Oncology's key executives? ZIOPHARM Oncology's management team includes the folowing people: Dr. Laurence James Neil Cooper, CEO & Director (Age 54)Dr. David M. Mauney M.D., Pres (Age 50)Mr. Kevin G. Lafond, Sr. VP of Fin., Chief Accounting Officer & Treasurer (Age 63)Ms. Lynn M. Ferrucci PHR, Sr. VP of HR, Facilities, IT & Admin.Mr. David Connolly, VP of Corp. Communications & Investor Relations Who are ZIOPHARM Oncology's major shareholders? ZIOPHARM Oncology's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Sanders Morris Harris LLC (0.11%), Janney Montgomery Scott LLC (0.07%), Allred Capital Management LLC (0.01%) and Alpine Global Management LLC (0.01%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney, Groot Eleanor De, Kevin G Lafond, Laurence James Neil Cooper and Robert Hadfield. View Institutional Ownership Trends for ZIOPHARM Oncology. Which major investors are buying ZIOPHARM Oncology stock? ZIOP stock was acquired by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Alpine Global Management LLC, Janney Montgomery Scott LLC and Allred Capital Management LLC. View Insider Buying and Selling for ZIOPHARM Oncology. How do I buy shares of ZIOPHARM Oncology? Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is ZIOPHARM Oncology's stock price today? One share of ZIOP stock can currently be purchased for approximately $4.42. How big of a company is ZIOPHARM Oncology? ZIOPHARM Oncology has a market capitalization of $800.15 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-53,120,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. ZIOPHARM Oncology employs 48 workers across the globe.View Additional Information About ZIOPHARM Oncology. What is ZIOPHARM Oncology's official website? The official website for ZIOPHARM Oncology is http://www.ziopharm.com/. How can I contact ZIOPHARM Oncology? ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected] MarketBeat Community Rating for ZIOPHARM Oncology (NASDAQ ZIOP)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 356 (Vote Outperform)Underperform Votes: 387 (Vote Underperform)Total Votes: 743MarketBeat's community ratings are surveys of what our community members think about ZIOPHARM Oncology and other stocks. Vote "Outperform" if you believe ZIOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZIOP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/26/2020 by MarketBeat.com StaffFeatured Article: What sectors are represented in the Nikkei Index?
